On March 3, 2022 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, reported it will sponsor and present an industry satellite symposium at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Therapeutics Conference, being held in-person March 10-12, 2022 at the Hyatt Regency, New Orleans, Louisiana (Press release, Cytori Therapeutics, MAR 3, 2022, View Source [SID1234609472]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the symposium are as follows:

Title Radiolabeled NanoLiposomes: A Novel Targeted Treatment for Rare and Central Nervous System Cancers
Date March 12, 2022 at 7:15 – 8:00 a.m. CT
Location Hyatt Regency, Elite B Main Meeting Room, New Orleans, Louisiana
Presenter Norman LaFrance, MD, ME, FACP, FACNP, FACNM; Chief Medical Officer and Senior Vice President at Plus Therapeutics
A copy of the presentation will be made available under the Presentations tab of the Investors section of the Company’s website following the symposium at View Source